Back to search

National and Kapodistrian University of Athens

Predicting therapeutic benefit of alemtuzumab in aggressive multiple sclerosis by measuring B cell tolerance checkpoint integrity

Abstract

dc:description

Introduction: Multiple sclerosis (MS) is the most prevalent autoimmune disorder of the central nervous system, categorized into various subtypes, with relapsing-remitting MS (RRMS) being the most common. The high clinical efficacy of anti-CD20 therapies has highlighted the crucial role of B cells in disease pathogenesis. In RRMS, a defective peripheral tolerance checkpoint has been demonstrated. The monoclonal antibody (mAb) alemtuzumab targets CD52+ immune cells, mainly T and B cells, inducing their transient depletion. Although alemtuzumab is highly effective in eliminating MS activity, its application is associated with the frequent development of secondary autoimmune phenomena, most commonly thyroid-related. Whether these effects are linked to an alteration of B cell tolerance mechanisms is currently not known. Objectives: This dissertation aims to determine whether alemtuzumab influences B cell tolerance mechanisms by evaluating the integrity of the peripheral B cell tolerance checkpoint and the B cell receptors (BCRs) repertoire, in conjunction with clinical outcomes. Methods: To evaluate peripheral B cell tolerance checkpoint integrity in patients and controls, we constructed 138 recombinant mAbs from single mature naïve B cells and tested their poly- and autoreactivity. We examined three healthy donors (HDs), three immunotherapy-naïve MS patients, and six patients treated with alemtuzumab at comparable time points post-treatment (mean ± SD 3.8 ± 0.39 years). Moreover, we investigated BCR repertoire parameters by performing next-generation sequencing (NGS) and assessing tolerance mechanisms in the same subject groups. Results: Polyreactive and autoreactive fraction means did not differ significantly among the three subgroups. Presence of a high or low autoreactive fraction of naïve B cells in patients treated with alemtuzumab did not correlate with secondary autoimmunity at the time of sampling and with future MS activity, and therefore most likely reflects stochastic variation in the context of immune reconstitution. In BCR repertoire analysis, alemtuzumab-treated patients showed lower mean naïve complementarity-determining region 3 (CDR3) net charge compared to HDs (P=0.0036), an interesting yet isolated finding warranting further investigation. Conclusions: The transient CD52 depletion did not appear to significantly impact the main aspects of peripheral B cell tolerance, as evaluated through naïve B cell cloning and BCR NGS. Additionally, these tolerance parameters were not linked to secondary autoimmunity. This combined methodological approach may also be relevant for other immune reconstitution therapies.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Alexaki, Anastasia
  • Αλεξάκη, Αναστασία

Subjects

dc:subject × 14

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/61222

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Alexaki, Anastasia; Αλεξάκη, Αναστασία. Predicting therapeutic benefit of alemtuzumab in aggressive multiple sclerosis by measuring B cell tolerance checkpoint integrity. National and Kapodistrian University of Athens, 2026. http://hdl.handle.net/10442/hedi/61222